Type 2 diabetes mellitus is associated with a considerably increased risk for development of cardiovascular disease (1, 2) . Aggressive risk factor management is an important mean for reducing the cardiovascular morbidity in this patient group which implies accurate risk stratification. Poorly controlled blood pressure and glycemia seem to be significantly involved in the development process of cardiovascular disease in patients with type 2 diabetes (3, 4) . Besides traditional risk markers the acute phase protein C-reactive protein (CRP) has turned out as an important cardiovascular risk predictor in the general population and patients with type 2 diabetes (5, 6) . To further improve the identification of patients with type 2 diabetes who are exposed to a particularly high cardiovascular risk, detection of additional independent risk markers might be useful.
Nitric oxide which is synthesized by nitric oxide synthases is an important antiatherogenic molecule (7). As initially described by Vallance et al. an endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), occurs in significant amounts in peripheral blood (8) . Since this discovery numerous clinical studies have been performed which found elevated circulating ADMA concentrations in humans suffering from diseases associated with increased cardiovascular risk. Different prospective cohort studies in selected patient groups suggested ADMA as an independent predictor of cardiovascular morbidity (9) (10) (11) (12) . In a cross-sectional study ADMA was associated with macrovascular disease in patients with type 2 diabetes (13) . However, the predictive role of ADMA for the occurrence of cardiovascular events in type 2 diabetes has not been examined prospectively until now.
We hypothesized that ADMA predicts cardiovascular events in patients with type 2 diabetes. Further, we sought to investigate if measurement of circulating ADMA concentrations adds to the predictive value of the well established risk marker CRP in patient with type 2 diabetes. It was recently reported that long-term supplementation of the precursor of nitric oxide, L-arginine, improves endothelial function, oxidative stress, glucose metabolism and insulin sensitivity in patients with type 2 diabetes (14, 15) . We determined L-arginine plasma concentrations to explore if L-arginine is related to cardiovascular risk in type 2 diabetes.
Research design and methods
Clinical investigations were approved by the Institutional Review Board and were conducted in accordance with the guidelines of the Declaration of Helsinki and informed consent was obtained from the study participants. This study was designed as prospective cohort study. Patients with type 2 diabetes duration of at least 2 years attending a speciality outpatient department for diabetes between September 2003 and March 2004 were included in this cohort study. All subjects were on stable antidiabetic therapy for at least 6 months. No life-style restrictions were imposed, but all patients were stimulated to adhere to an appropriate nutrition program, weight control and to perform regular exercise. At the time of inclusion, demographic data, clinical characteristics, and current medication of the patients were recorded with special attention to cardiovascular risk factors and comorbidities. Age, sex, smoking habits, hyperlipidemia, arterial hypertension, coronary artery disease, history of myocardial infarction, and stroke were assessed. Arterial hypertension was diagnosed in patients with resting blood pressure values >140/90 mmHg, and was assumed to be present in patients with a history of hypertension taking antihypertensive drugs. Hyperlipidemia was defined as present lipid lowering therapy or elevation of blood lipids (LDL-cholesterol >130 mg/dl, triglycerides >200 mg/dl).
Subjects with end-stage renal disease were not included.
Laboratory investigations
Venous blood was drawn after an overnight fast for determination of ADMA, Larginine, CRP and routine clinical parameters. Blood levels of creatinine, HbA1c, blood glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and high-sensitivity C-reactive protein (CRP) were measured by standard laboratory methods. Glomerular filtration rate was calculated with the Modification of Diet in Renal Disease Study Group formula (16). For measurement of ADMA and Larginine, plasma was subjected to cation exchange solid-phase extraction and analysed by high-performance liquid chromatography (17,18). The coefficients of variation for inter-and intra-assay variations tested with a pooled plasma sample were below 3% for all analytes. The detection limit for dimethylarginines was 0.04 µmol/l.
Study end point and follow-up
The occurrence of the first cardiovascular events (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, stroke, carotid revascularization, all-cause mortality) was defined as composite end point. Patients were re-examined at 2 -6 month intervals until June 2006. At these visits routine adjustment of medication was performed to optimize glycemia, blood lipids and blood pressure in all patients. The occurrence of cardiovascular events was confirmed by review of hospital records.
Statistics
Continuous data are presented as medians (interquartile range). Categorical data are given as counts (percentages). Mann Whitney U test was applied for univariate comparison of continuous data and Spearman rank correlation for assessment of associations between continuous variables. Univariate and multivariate Cox proportional hazards analysis was used to assess the independent effect of ADMA and CRP on the composite end point and to adjust for potential confounders. To assess the joint effect of ADMA and CRP the study cohort was stratified into 3 groups according to tertiles of ADMA and CRP (group 1: neither ADMA nor CRP in the highest tertile; group 2: ADMA or CRP in the highest tertile and the other parameter in the lowest tertile; group 3: ADMA and CRP or one of them in the highest tertile and none in the lowest). Tertiles of continuous variables were included as confounders if these variables were associated with ADMA or CRP according to Spearman rank correlation coefficients. Categorical variables were entered into the model if they influenced ADMA or CRP according to univariate analysis. In addition, adjustment for age and sex was performed. For analysis of the joint predictive role of ADMA and CRP confounders from both models were included. Results of the Cox proportional hazards model are presented as hazard ratio and 95% confidence interval (CI) as well as survival curves. A two-sided P<0.05 was considered as statistically significant. Considering previous studies in patients with type 2 diabetes we estimated a cardiovascular event rate of 25% during the follow-up period. According to this a study in 100 patients has 80% power to detect a hazard ratio of 2.0 for the occurrence of cardiovascular events for tertiles of ADMA or CRP (two-sided hypothesis testing, α = 0.05). Therefore we aimed to include at least 100 patients. Calculations were performed with SPSS for Windows (Version 14.0; SPSS Inc, Chicago, Ill).
Results
One hundred thirty five subjects with type 2 diabetes were suitable for the study. Ten patients were excluded due to missing clinical follow-up data on cardiovascular events. The remaining 125 patients (93%) were included into the analysis.
Median ADMA, L-arginine and CRP plasma concentration of all patients were 0.57 µmol/l (IQR 0.50 -0.66), 63 µmol/l (IQR 49 -76) and 4.0 mg/l (1.9 -7.0), respectively. Other baseline parameters are presented in table 1. ADMA and CRP were both elevated in patients with a history of macrovascular disease (table 2) . ADMA correlated negatively with glomerular filtrations rate and CRP was associated with HDL-cholesterol (table 1) .
During a median follow-up of 21 (IQR 11-27) months 83 macrovascular events occurred in 48 patients (38%) including 10 myocardial infarctions (12%), 11 strokes (13%), 38 percutaneous coronary interventions or coronary artery bypass grafts (46%), 13 endovascular or surgical interventions in leg arteries (16%) and 11 deaths (13%). Patients with ADMA in the highest tertile had a significantly higher hazard ratio for macrovascular events compared to those in the lower tertiles before and after adjustment for age, sex, history of macrovascular disease and glomerular filtration rate. Twenty two endpoints (46%) were observed in patients with ADMA in the highest tertile. Patients with CRP in the highest tertile also had a significantly increased hazard ratio for macrovascular events before and after adjustment for age, sex, history of macrovascular disease and HDL-cholesterol (table 3) . Twenty endpoints (42%) occurred in patients with CRP in the highest tertile.
Patients with either ADMA or CRP or both in the highest tertile had a remarkably increased hazard ratio for cardiovascular events before and after adjustment for age, sex, history of macrovascular disease, glomerular filtration rate and HDLcholesterol. These were even higher than the hazard ratios found for ADMA and CRP alone ( 
Conclusions
Both, ADMA and CRP predict the occurrence of cardiovascular events in patients with type 2 diabetes. Combining both parameters showed that ADMA augments the predictive value of CRP as a cardiovascular risk marker. Patients with ADMA or CRP in the highest tertile and none of these parameters in the lowest tertile had a 4.5 times increased risk for the occurrence of cardiovascular events compared to those with neither ADMA nor CRP in the highest tertile. This imposes an important role of ADMA for cardiovascular risk stratification adding to determination of CRP and traditional cardiovascular risk markers. A significant additional predictive value of ADMA to CRP for all-cause and cardiovascular mortality in patients with end-stage renal disease has already been shown in a previous study (19). Our study extends these findings to patients with type 2 diabetes. Risk stratification in patients with type 2 diabetes is of particular relevance. Patients with type 2 diabetes are prone to a dramatically high risk for cardiovascular events. This is reflected by the fact that subjects with diabetes without prior evidence of coronary heart disease have a similar risk to die from coronary heart as subjects with prior coronary heart disease without diabetes (20).
The predictive role of ADMA was independent of traditional cardiovascular risk markers and preexisting cardiovascular disease. Elevated ADMA has been found in patients with renal failure indicating that ADMA is excreted by the kidneys (8) . In subjects with normal renal function circulating concentrations of ADMA are mainly determined by its degradation by dimethylamino dimethylarginine hydrolases (DDAH) (21). ADMA correlated with glomerular filtration rate suggesting that renal excretion of this methylarginine plays a role for its plasma concentrations in our cohort of patients with type 2 diabetes.
It was previously reported that LDLcholesterol suppressed DDAH activity and thereby increased ADMA in an vitro experiment (22). Further, it was shown that ADMA is elevated in patients with hyperlipidemia (6,23) and essential hypertension (24). But ADMA was not associated with hyperlipidemia or elevated blood pressure in our study which was also found in other clinical trials (11, 12) . The influence of concomitant medication in our patients could have obscured a possible relationship between ADMA and these risk factors. However, ADMA concentrations were not different in patients on statin therapy in the present cohort. Most studies investigating ADMA and statin therapy provided similar results (25-27) with exception of a study describing an ADMA lowering effect of rosuvastatin (28). Therefore, an influence of statin therapy on the relationship between ADMA and hyperlipidemia seems unlikely.
CRP was independently associated with future cardiovascular events in the present study which was previously found in patients with type 2 diabetes (6, 29, 30 ). This confirms the importance of inflammation for incident cardiovascular disease. However, CRP and other traditional cardiovascular risk markers may not sufficiently predict the cardiovascular risk of patients with type 2 diabetes. As shown in the present study the addition of ADMA to CRP enhances cardiovascular risk prediction in patients with type 2 diabetes. More accurate risk assessment by additional ADMA determination could lead to more stringent management of cardiovascular risk factors and might therefore be of major clinical relevance. Future prospective studies will be needed to examine if risk marker guided therapy will lead to improvement of cardiovascular morbidity and mortality in patients with type 2 diabetes. As a limitation of the study only patients attending a specialized outpatient clinic who might have a more pronounced cardiovascular risk profile than the general diabetic population were included in this analysis. This could explain the rather high incidence of cardiovascular events found in our study. Larger prospective studies with longer follow-up will be necessary to strengthen our findings.
Piatti et al. reported that L-arginine administration has beneficial effects on endothelial function and the cardiovascular risk profile in patients with type 2 diabetes (15). L-arginine was not associated with future cardiovascular events in the present cohort. Therefore, our results do not support a protective role of endogenous circulating L-arginine. Cumulative survival without cardiovascular events in patients with type 2 diabetes according to joint effects of asymmetric dimethylarginine and C-reactive protein adjusted for age, sex, history of macrovascular disease, glomerular filtrations rate and HDL-cholesterol (group 1: neither ADMA nor CRP in the highest tertile; group 2: ADMA or CRP in the highest tertile and the other parameter in the lowest tertile; group 3: ADMA and CRP or one of them in the highest tertile and none in the lowest).
